(Q34511936)

2 August 2017

1 reference

title

Immune-based therapies: a review of clinical endpoints used in trials of selected immunologic agents (English)

1 reference

2 August 2017

author name string

Forum for Collaborative HIV Research.

series ordinal

1

1 reference

2 August 2017

publication date

1 January 2002

1 reference

2 August 2017

1 reference

2 August 2017

volume

3

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

58-88

1 reference

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

Increased concentrations of soluble tumor necrosis factor receptor 75 but not of soluble intercellular adhesion molecule-1 are associated with the decline of CD4+ lymphocytes in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

Soluble tumor necrosis factor receptor: inhibition of human immunodeficiency virus activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

Soluble tumor necrosis factor receptors inhibit phorbol myristate acetate and cytokine-induced HIV-1 expression chronically infected U1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

Subcutaneous interleukin-2 in combination with anti-retroviral therapy for treatment of HIV-1-infected subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

Characterization of a novel subset of CD8(+) T cells that expands in patients receiving interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

Interleukin-12 enhancement of antigen-specific lymphocyte proliferation correlates with stage of human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

Effect of recombinant human granulocyte-macrophage colony-stimulating factor on HIV-related leukopenia: a randomized, controlled clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

A randomized, placebo-controlled trial of granulocyte-macrophage colony-stimulating factor and nucleoside analogue therapy in AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

Resistance to human immunodeficiency virus type 1 in vitro as a surrogate of vaccine-induced protective immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp120 prime-boost HIV-1 vaccine. NIAID AIDS Vaccine Evaluation Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

Plasma levels of soluble CD30, tumour necrosis factor (TNF)-alpha and TNF receptors during primary HIV-1 infection: correlation with HIV-1 RNA and the clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFT44-2D7Q-UJFD-R6RY

10.1310/FT44-2D7Q-UJFD-R6RY

21 January 2018

Identifiers

DOI

1 reference

release_au64t5fosvfcrko3so3jsmigvu

2 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/au64t5fosvfcrko3so3jsmigvu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference